WO2008055851A1 - Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidylmethyl)-benzamide and salts thereof - Google Patents

Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidylmethyl)-benzamide and salts thereof Download PDF

Info

Publication number
WO2008055851A1
WO2008055851A1 PCT/EP2007/061820 EP2007061820W WO2008055851A1 WO 2008055851 A1 WO2008055851 A1 WO 2008055851A1 EP 2007061820 W EP2007061820 W EP 2007061820W WO 2008055851 A1 WO2008055851 A1 WO 2008055851A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
trifluoroethoxy
process according
trifluorethoxy
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/061820
Other languages
French (fr)
Other versions
WO2008055851A8 (en
Inventor
Daina Zicane
Janis Jaunbergs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grindeks JSC
Original Assignee
Grindeks JSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grindeks JSC filed Critical Grindeks JSC
Priority to US12/312,322 priority Critical patent/US20100056794A1/en
Priority to JP2009535082A priority patent/JP2010508331A/en
Priority to EA200900356A priority patent/EA200900356A1/en
Priority to CA002660364A priority patent/CA2660364A1/en
Priority to AU2007316692A priority patent/AU2007316692A1/en
Priority to MX2009004648A priority patent/MX2009004648A/en
Priority to BRPI0714989-1A priority patent/BRPI0714989A2/en
Priority to EP07822153A priority patent/EP2079692A1/en
Publication of WO2008055851A1 publication Critical patent/WO2008055851A1/en
Publication of WO2008055851A8 publication Critical patent/WO2008055851A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01Preparation of ethers
    • C07C41/09Preparation of ethers by dehydration of compounds containing hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/205Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
    • C07C43/2055Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring containing more than one ether bond

Definitions

  • the present invention relates to an improved process for the preparation of 2,5-£vs(2,2,2-trifluoroethoxy)-M(2-piperidylmethyl)benzamide (international non-proprietary name - "Flecainide”) and salts, in particularly pharmaceutically acceptable salts, thereof.
  • Flecainide base pharmaceutically acceptable salts thereof, and in particular its hydrochloride form, are generally described in US-A-3900481.
  • Flecainide is an active ingredient used in human therapy as an antiarrhythmic agent, as described in US-A-4005209.
  • US-B-4024175 describes the preparation of Flecainide starting from 1 ,4- dibromobenzene which is transformed by reaction with trifluoroethoxy compounds and acetylating agents into 2,5-b/s ⁇ 2,2,2- trifluoroethoxy)acetophenone, which after subsequent gives Flecainide.
  • Two process for preparing Flecainide disclosed in GB-A-2045760 starts from 2,5-b/s (2,2,2-trifluoroethoxy)benzoic acid.
  • 2,5- ⁇ /5 (2,2,2- trifluoroethoxy)benzoic acid is prepared by a multistage process, comprising the conversion of 1 ,4-dibromobenzene into ⁇ ,4-bis(2,2,2- trifluoroethoxy)benzene by reacting 8 equivalents of 2,2,2-trifluoroethanol per mol of dibromobenzene, and then acetylating the 1 ,4-£/s(2,2,2- trifluoroethoxy) benzene to form 2,5-£/s(2,2,2-trifluoroethoxy) acetophenone.
  • the 2,5-£/s(2,2,2-trifluoroethoxy)acetophenone then is oxidized to the corresponding 2,5-£/s(2,2,2-trifluoroethoxy
  • the 2,5-£/s(2,2,2-trifluoroethoxy)benzoic acid then is converted into its acid chloride and reacted with 2-(aminomethyl)piperidine to form Flecainide in one step.
  • the acid chloride can be reacted with 2-(aminomethyl)pyridine, followed by catalytic hydrogenation of the pyridine ring, to form Flecainide.
  • a disadvantage of using 1 ,4-dibrombenzene to form 1 ,A-bis ⁇ 2,2,2- trifluoroethoxy)benzene is that the process requires the reaction of 8 equivalents of 2,2,2-trifluoroethanol while only 2 equivalents are theoretically needed.
  • the one step-process has a further disadvantage in that the acid chloride reacts non-selectively with both nitrogen atoms of the 2-(aminomethyl)pi- peridine resulting in a mixture of the two acylated isomers. This is the main reason why the two-step process via the pyridine intermediate presently is commercially preferred.
  • a further disadvantage is due to the fact the acid chloride intermediate is a liquid which cannot be stored for a long period of time but must be used immediately after its preparation.
  • the multi step-process for obtaining 2,5-£/s(2,2,2-trifluoroethoxy)benzoic acid can also be mentioned as a further disadvantage.
  • 2,5-£/s(2,2,2-trifluoroethoxy)benzoic acid can also be prepared from 1- bromo-4-fluorobenzene (see WO-A-02066413) or from 2-bromo-5- chlorobenzoic acid (see WO-A-9902498).
  • the method disclosed in WO-A-02066413 is a multi-step process that includes obtaining alkyl 2,5-£/s(2,2,2-trifluoroethoxy)phenylglyoxalate as an intermediate product which is oxidized to form 2,5-£/s(2,2,2-trifluoro- ethoxy)benzoic acid.
  • this approach has only a limited commercial utility due to the high cost.
  • the objective underlying the present invention is to overcome the above disadvantages of the prior art.
  • R is a 2-piperidyl or 2-pyridyl radical, and salts, in particular pharmaceutically acceptable salts, thereof, the process comprising the following steps: a) preparation of a compound of formula Il
  • Xi and X2 each are F, Cl, Br and I, by reaction of the 2,5- dihalotoluene of formula I with a strong base and 2,2,2-trifluoroethanol in the presence of a catalyst in an aprotic solvent to form 2,5-b/s ⁇ 2,2,2- trifluoroethoxy)toluene of formula II, [0024] b) oxidation of compound Il to yield 2,5-£/s(2,2,2-trifluorethoxy)benzoic acid of formula III;
  • Subject-matter of the present invention is also a process for the preparation of the key intermediate 2,5-£/s(2,2,2-trifluoroethoxy)benzoic acid beginning with a starting material of formula I, where Xi and X2 each are F 1 CI 1 Br and I.
  • Reaction of starting material of formula I with 2,2,2-trifluoroethanol in the presence of a base and a suitable catalyst such as a copper catalyst provides compounds of formula Il in high yield (e.g., 92 %).
  • a suitable solvent e.g., water
  • the method of the present invention involves the initial preparation of 2,5-£/s(2,2,2-trifluoroethoxy)toluene (II) by reacting 2,5- dihalotoluene (I) with 2,2,2-trifluoroethanol in the presence of a strong base and a copper containing catalyst.
  • the 2,2,2-trifluoroethanol reacts in about 2-10-fold molar excess of the 2,5-dihalotoluene to replace the 2,5- dihalotoluene aromatic halogen substituents with trifluoroethoxy groups.
  • Bases that enable the reaction include alkali metals, e.g., metallic sodium.
  • a copper containing material is used as a catalyst in the reaction, e.g., copper (II) sulphate.
  • a catalyst in the reaction e.g., copper (II) sulphate.
  • ⁇ /, ⁇ /-dimethylformamide can be used as an aprotic solvent.
  • the best mode for carrying out the reaction is a temperature of about 85 to 105°C.
  • the 2,5-dibromo- toluene (I), where Xi and X2 is Br, is reacted with sodium 2,2,2-trifluoro- ethoxide (produced by reacting 2,2,2-trifluoroethanol with Na) in N, N- dimethylformamide in the presence of CuSO 4 at about 85 to 105°C.
  • the 2,5-6/s(2,2,2-trifluoroethoxy)toluene (II) is thereafter oxidized in the presence of a suitable oxidant to produce 2,5-b/s(2,2,2- trifluorethoxy)benzoic acid (III).
  • a suitable oxidant potassium permanganate and sodium permanganate can be used.
  • 2,5-6/s(2,2,2-trifluorethoxy)-M(pyrid-2-yl-methyl)benzamine (IV) is hydro- genated in the presence of a platinum or palladium on carbon catalyst in a suitable solvent, e.g., water.
  • a suitable solvent e.g., water.
  • the reduction can be performed in a hydrogen atmosphere at 4-6 atmospheres.
  • the reaction may be carried out within about 3 hours.
  • the residual filtrate is reacted with a suitable base, e.g. NaOH, to produce the Flecainide free base.
  • the Flecainide free base then is converted into Fecainide acetate (V).
  • the free base is thus reacted with glacial acetic acid to form the acetate.
  • the reaction may be preformed at 31 0 C.
  • the mixture was heated to 85°C and treated with potassium permanganate in 6 portions of 34 grams each, for a total of 204 g (1.29 mol).
  • the permanganate addition rate was such as to maintain the temperature at 90-100°C.
  • the reaction mixture was maintained at 85-95°C for an additional hour and filtered while hot.
  • the manganese oxide precipitate was washed with water and the washings were combined with the pyridine-water filtrate, then cooled to 5-10°C and filtered to remove the unreacted starting material.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)

Abstract

Process for the preparation of 2,5-bis(2,2,2-trifluoroethoxy)-N-(2- piperidylmethyl)benzamide, its pharmaceutically acceptable salts and important intermediates thereof that involves 1,4-dihalotoluenes as starting material. The method involves a technique for preparing the starting material 2,5-bis(2,2,2-trifluroethoxy)toluene in high yields by reacting 1,4- dibromotoluene with 2,2,2-trifluoroethanol in presence of a base and a copper-containing catalyst.

Description

Description
PROCESS FOR THE PREPARATION OF 2,5-BIS-(2,2,2-TRIFLUOROETHOXY)- N-(2-PIPERIDYLMETHYL)-BENZAMIDE AND SALTS THEREOF Field of the invention
[0001] The present invention relates to an improved process for the preparation of 2,5-£vs(2,2,2-trifluoroethoxy)-M(2-piperidylmethyl)benzamide (international non-proprietary name - "Flecainide") and salts, in particularly pharmaceutically acceptable salts, thereof.
Background art
[0002] Flecainide base, pharmaceutically acceptable salts thereof, and in particular its hydrochloride form, are generally described in US-A-3900481.
[0003] Flecainide is an active ingredient used in human therapy as an antiarrhythmic agent, as described in US-A-4005209.
[0004] There are many processes described in the art for the synthesis of this compound, for example:
[0005] US-B-4024175 describes the preparation of Flecainide starting from 1 ,4- dibromobenzene which is transformed by reaction with trifluoroethoxy compounds and acetylating agents into 2,5-b/s{2,2,2- trifluoroethoxy)acetophenone, which after subsequent gives Flecainide.
[0006] One process for preparing Flecainide disclosed in GB-A-2045760 starts from 2,5-b/s (2,2,2-trifluoroethoxy)benzoic acid. 2,5-^/5 (2,2,2- trifluoroethoxy)benzoic acid is prepared by a multistage process, comprising the conversion of 1 ,4-dibromobenzene into λ ,4-bis(2,2,2- trifluoroethoxy)benzene by reacting 8 equivalents of 2,2,2-trifluoroethanol per mol of dibromobenzene, and then acetylating the 1 ,4-£/s(2,2,2- trifluoroethoxy) benzene to form 2,5-£/s(2,2,2-trifluoroethoxy) acetophenone. The 2,5-£/s(2,2,2-trifluoroethoxy)acetophenone then is oxidized to the corresponding 2,5-£/s(2,2,2-trifluoroethoxy)benzoic acid.
[0007] The 2,5-£/s(2,2,2-trifluoroethoxy)benzoic acid then is converted into its acid chloride and reacted with 2-(aminomethyl)piperidine to form Flecainide in one step. Alternatively, the acid chloride can be reacted with 2-(aminomethyl)pyridine, followed by catalytic hydrogenation of the pyridine ring, to form Flecainide. [0008] A disadvantage of using 1 ,4-dibrombenzene to form 1 ,A-bis{2,2,2- trifluoroethoxy)benzene is that the process requires the reaction of 8 equivalents of 2,2,2-trifluoroethanol while only 2 equivalents are theoretically needed. The use of less than 8 equivalents of 2,2,2- trifluoroethanol, however, results in an incomplete conversion into 1 ,4-£/s (2,2,2-trifluoroethoxy)benzene with the starting material and 1-bromo-4- (2,2,2-trifluoroethoxy)benzene as the main impurities.
[0009] The one step-process has a further disadvantage in that the acid chloride reacts non-selectively with both nitrogen atoms of the 2-(aminomethyl)pi- peridine resulting in a mixture of the two acylated isomers. This is the main reason why the two-step process via the pyridine intermediate presently is commercially preferred. A further disadvantage is due to the fact the acid chloride intermediate is a liquid which cannot be stored for a long period of time but must be used immediately after its preparation.
[0010] The multi step-process for obtaining 2,5-£/s(2,2,2-trifluoroethoxy)benzoic acid can also be mentioned as a further disadvantage.
[0011] 2,5-£/s(2,2,2-trifluoroethoxy)benzoic acid can also be prepared from 1- bromo-4-fluorobenzene (see WO-A-02066413) or from 2-bromo-5- chlorobenzoic acid (see WO-A-9902498).
[0012] For the preparation of 2,5-£/s(2,2,2-trifluoroethoxy)benzoic acid from 2- bromo-5-chlorobenzoic acid sodium hydride in combination with N, N- dimethylformamide is used. However, it is known that using sodium hydride in combination with Λ/,/V-dimethylformamide can lead to explosion (see BUCKLEY, J.. "Report on thermal reaction", published in "Chem. Eng. News". 1982, vol.60, no.28, p.5. , POND, DAVID, "Sodium hydride and DMF", published in "Chem. Eng. News". 1982, vol. 60, no. 37, p. 5,43. This is the main disadvantage of the process disclosed in WO-A-9902498 Furthermore, the use of 1-bromo-4-fluorobenzene as a starting material is comparatively expensive.
[0013] The method disclosed in WO-A-02066413 is a multi-step process that includes obtaining alkyl 2,5-£/s(2,2,2-trifluoroethoxy)phenylglyoxalate as an intermediate product which is oxidized to form 2,5-£/s(2,2,2-trifluoro- ethoxy)benzoic acid. However, this approach has only a limited commercial utility due to the high cost.
[0014] The process disclosed in WO-A-9902498 starts from the cyanomethyl ester of 2,5-£/s(2,2,2-trifluoroethoxy)benzoic acid which selectively reacts with 2-(aminomethyl)piperidine to furnish Flecainide.
[0015] The process disclosed in WO-A-02066413 starts from 2,5-b/s{2,2,2- trifluoroethoxy)benzene which is converted into 2,5-b/s{2,2,2- trifluoroethoxy)benzoyl chloride, and then is reacted with 2,2,2- trifluoroethanol in the presence of an appropriate base to produce 2,5- 6/s(2,2,2-trifluoroethoxy)benzoate. Finally, the 2,5-b/s{2,2,2- trifluoroethoxy)benzoate is reacted with 2-(aminomethyl)pyridine to form 2.5-b/s{2, 2, 2-trifluoroethoxy )pyridylbenzamide which then is reduced to form Flecainide.
[0016] The prior art process for the manufacture of 2,5-£/s(2,2,2-trifluorethoxy)-Λ/- (pyrid-2-yl-methyl)benzamide has several disadvantages which have been overcome by the present invention namely:
1. the introduction of the trifluorethoxy group substituents at the aromatic ring was previously achieved by employing costly sulfonate leaving groups, such as trifluoromethane sulfonate or perfluorobutane sulfonate or by treating 1 ,4-dibromobenzene or 5-bromo-2-chlorobenzoic acid with 2,2,2-trifluorethanol in dimethylformamide in the presence of NaH;
2. the derivatization of the trifluorethoxy substituted aromatic system to produce 2,5-£/s(trifluorethoxy)benzoic acid or its derivatives was conducted by Friedel-Crafts acylation, followed by chlorination; and
3. the 2,5-b/s{2, 2, 2-trifluorethoxy)benzoic acid conversion into 2,5-b/s (2,2,2-trifluorethoxy)-Λ/-(pyrid-2-yl-methyl)benzamide previously required the preparation of acyl chloride or trichloro acetophenone, the handling of these intermediates representing unnecessary challenges.
Disclosure of the invention Technical problem [0017] The objective underlying the present invention is to overcome the above disadvantages of the prior art. In particular it is the objective of the present invention to provide a novel commercial process for the preparation of Flecainide acetate salt or their salts, in particular their pharmaceutically acceptable salts, starting from commercially available dihalotoluenes of formula I, where Xi and X2 βach are F, Cl, Br or I.
Technical solution
[0018] The above objective is achieved according to the present invention by a sequential combination of four process steps, starting from 2,5- dibromotoluene:
1. replacement of the 2,5-dibromotoluene aromatic bromine substituents by trifluoroethoxy groups, and, thus, preparation of 2,5-£/s(trifluoro- ethoxy)toluene or any of the intermediate substitution products 2- bromo-5-trifluorethoxytoluene and 5-bromo-2-trifluorethoxytoluene,
2. oxidation of 2,5-£/s(trifluorethoxy)toluene to produce 2,5- £/s(trifluorethoxy)benzoic acid,
3. activation of 2,5-£/s(trifluorethoxy)benzoic acid in-situ with a chloroformate, and substitution of the leaving carbonate group with 2- (aminomethyl)pyridine, and
4. hydrogenation of 2,5-£/s(2,2,2-trifluorethoxy)-Λ/-(pyrid-2-yl- methyl)benzamide to obtain Flecainide acetate.
Advantageous effects
[0019] The following Reaction Scheme 1 outlines the present method of preparation of Flecainide acetate. The method includes the following advantages:
1. use of more environmentally friendly materials and solvents, respectively, which have low toxicity;
2. use of metallic sodium instead sodium hydride in combination with N, N - dimethylformamide as safer method in industrial production;
3. production of the desired final product in higher yields;
4. amenability for large scale production which does not require specialized equipment. [0020] Reaction Scheme 1 [0021]
Figure imgf000006_0001
( III )
Figure imgf000006_0002
Figure imgf000006_0003
[0022] Thus, the subject matter of the present invention is a process for preparing a compound of formula Vl:
Figure imgf000007_0001
wherein R is a 2-piperidyl or 2-pyridyl radical, and salts, in particular pharmaceutically acceptable salts, thereof, the process comprising the following steps: a) preparation of a compound of formula Il
Figure imgf000007_0002
from a compound of formula I
Figure imgf000007_0003
wherein Xi and X2 each are F, Cl, Br and I, by reaction of the 2,5- dihalotoluene of formula I with a strong base and 2,2,2-trifluoroethanol in the presence of a catalyst in an aprotic solvent to form 2,5-b/s{2,2,2- trifluoroethoxy)toluene of formula II, [0024] b) oxidation of compound Il to yield 2,5-£/s(2,2,2-trifluorethoxy)benzoic acid of formula III;
H
Figure imgf000008_0001
[0025] c) activating the benzoic acid of formula III with a carboxylic acid ester and thereafter reacting the mixed anhydride of benzoic acid of formula III with an amine of the formula RCH2NH2, where R is 2-pyridyl to obtain a compound of formula IV;
Figure imgf000008_0002
[0026] d) converting the compound of formula IV into a salt, to obtain compound of formula V, in particular into a pharmaceutically acceptable salt, thereof.
Figure imgf000008_0003
[0027] Subject-matter of the present invention is also a process for the preparation of the key intermediate 2,5-£/s(2,2,2-trifluoroethoxy)benzoic acid beginning with a starting material of formula I, where Xi and X2 each are F1CI1Br and I. [0028] Reaction of starting material of formula I with 2,2,2-trifluoroethanol in the presence of a base and a suitable catalyst such as a copper catalyst provides compounds of formula Il in high yield (e.g., 92 %).
[0029]
Figure imgf000009_0001
[0030] Compound of formula Il is oxidized with permanganate compounds like sodium permanganate or potassium permanganate to yield a compound of formula III, which is the main intermediate product for preparation of
Flecainide acetate, compound of formula V.
[0031] Compound of formula III is activated with a carboxylic acid ester and after reaction with the primary amino group of 2-(aminomethyl)pyridine produces compound of formula IV.
[0032] It is yet another subject-matter of present invention to prepare and use the intermediate 2,5-dibromotoluene for the manufacture of Flecainide acetate, compound of formula V.
[0033] Heterogeneous catalytic hydrogenation of compound IV in the presence palladium and platinum on carbon in a suitable solvent, e.g., water, is carried out in a solution of an aliphatic carboxylic acid (e.g. glacial acetic acid) for obtaining Flecainide acetate, compound of formula V.
Best mode for carrying out the invention
[0034] As indicated above, the method of the present invention involves the initial preparation of 2,5-£/s(2,2,2-trifluoroethoxy)toluene (II) by reacting 2,5- dihalotoluene (I) with 2,2,2-trifluoroethanol in the presence of a strong base and a copper containing catalyst. The 2,2,2-trifluoroethanol reacts in about 2-10-fold molar excess of the 2,5-dihalotoluene to replace the 2,5- dihalotoluene aromatic halogen substituents with trifluoroethoxy groups. [0035] Bases that enable the reaction include alkali metals, e.g., metallic sodium. A copper containing material is used as a catalyst in the reaction, e.g., copper (II) sulphate. For performing reaction Λ/,Λ/-dimethylformamide can be used as an aprotic solvent. The best mode for carrying out the reaction is a temperature of about 85 to 105°C.
[0036] In accordance with a practicularly preferred embodiment, the 2,5-dibromo- toluene (I), where Xi and X2 is Br, is reacted with sodium 2,2,2-trifluoro- ethoxide (produced by reacting 2,2,2-trifluoroethanol with Na) in N, N- dimethylformamide in the presence of CuSO4 at about 85 to 105°C.
[0037] The 2,5-6/s(2,2,2-trifluoroethoxy)toluene (II) is thereafter oxidized in the presence of a suitable oxidant to produce 2,5-b/s(2,2,2- trifluorethoxy)benzoic acid (III). As oxidants potassium permanganate and sodium permanganate can be used.
[0038] 2,5-£/s(2,2,2-trifluorethoxy)benzoic acid (III) is activated with ethyl chloroformate and thereafter is reacted with the primary amino group of 2- (aminomethyl)pyridine to yield 2,5-£/s(2,2,2-trifluorethoxy)-Λ/-(pyrid-2-yl- methyl)benzamide (IV).
[0039] 2,5-6/s(2,2,2-trifluorethoxy)-M(pyrid-2-yl-methyl)benzamine (IV) is hydro- genated in the presence of a platinum or palladium on carbon catalyst in a suitable solvent, e.g., water. The reduction can be performed in a hydrogen atmosphere at 4-6 atmospheres. The reaction may be carried out within about 3 hours. The residual filtrate is reacted with a suitable base, e.g. NaOH, to produce the Flecainide free base. The Flecainide free base then is converted into Fecainide acetate (V). The free base is thus reacted with glacial acetic acid to form the acetate. The reaction may be preformed at 310C.
[0040] The present invention will be described in more detail by referring to the following non-limiting examples. [0041] Example 1
[0042] Preparation of 2,5-A«s(2,2I2-trifluoroethoxy)toluene (II) [0043] 2,2,2-trifluoroethanol (55.0 g, 0.550 mol) was added to dioxane (125 ml_) in a glass vessel fitted with a reflux condenser. Sodium metal (11.5 g, 0.500 mol) was added in portions of 2-3 grams to the solution, resulting in a temperature increase from 22°C to 90°C. The solution was stirred at 85- 105°C until the sodium dissolution was completed, then N, N- dimethylformamide (100 ml_) was added, followed by 2,5-dibromotoluene (I) (42.5 g, 0.170 mol) and anhydrous copper (II) sulphate (2.9 g, 0.018 mol). The reaction mixture was stirred at 95-100°C for 4 hours, and then cooled to 25-300C and poured into 900 ml of a cold (5-100C) 40% aqueous methanol solution.
[0044] Concentrated hydrochloric acid was added (-25 ml_, 0.300 mol), until pH=1-2. The crystallization suspension was stirred for 1 hour at -5 to 00C, the solid white precipitate was filtered, after which the reaction vessel and the product cake on the filter were rinsed with 50 ml_ of water. The intermediate 2,5-£/s(2,2,2-trifluoroethoxy)toluene (II) was dried at ambient temperature and pressure for 5 hours, then at 22 to 24°C and at a reduced pressure for 4 hours. The 2,5-£/s(2,2,2-trifluoroethoxy)toluene was obtained as a white or off-white powder (45.5 g, 92%) having a melting point of 37°C to 42°C.
[0045] Example 2
[0046] Preparation of 2,5-£/s(2,2,2-trifluorethoxy)benzoic acid (III)
[0047] The 2,5-6/s(2,2,2-trifluoroethoxy)toluene (II) (220 g, 0.986 mol) was added to magnetically stirred pyridine (1550 ml_) at 18-23°C. The reaction mixture was stirred under a reflux. Thereafter a 10 % aqueous NaOH solution (20 ml_, 0.050 mol) and copper (II) sulphate (0.27 g, 0.0017 mol) were added to the reaction mixture.
[0048] The reaction mixture was heated at 81 °C for 1 hour at which point a 40% aqueous sodium permanganate solution (2290 g, 6.45 mol) was added in portions within a time period of 6.5 hours. After the addition of an aqueous sodium permanganate solution the reaction mixture was stirred at 83 to 93°C for 75 minutes. A precipitate of manganese oxides was separated by filtration at 80-95°C, the manganese oxides was rinsed on the filter with 5 liters of hot (80°C) water. The combined filtrates were cooled to 9°C in 50 minutes. [0049] The crystallization suspension was filtered to obtain damp cake of unreacted 2,5-£/s(2,2,2-trifluoroethoxy)toluene (II), which was removed thereafter.
[0050] The filtrate of reaction mixture was mixed with activated charcoal (20.0 g) and stirred for 75 minutes; the precipitate of charcoal was separated by filtration and liquid phase was acidified to pH=1-2 using concentrated HCI. The crystallization solution was filtrated and the product cake on the filter was rinsed with 200 ml_ of water.
[0051] The intermediate 2,5-b/s{2, 2, 2-trifluorethoxy)benzoic acid (III) was dried at reduced pressure for 18 hours. The 2,5-£/s(2,2,2-trifluorethoxy)benzoic acid was obtained as an off-white powder (210.2 g, 81.6%) having a melting point of 121 °C to 125°C.
[0052] Example 3
[0053] Pyridine (310 ml_), water (175 ml_) and 2,5-b/s{2,2,2- trifluoroethoxy)toluene (44.4 g, 0.154 mol) were mixed in a 1 liter round bottom flask, the pH was adjusted to 11-12 with sodium hydroxide.
[0054] The mixture was heated to 85°C and treated with potassium permanganate in 6 portions of 34 grams each, for a total of 204 g (1.29 mol). The permanganate addition rate was such as to maintain the temperature at 90-100°C. The reaction mixture was maintained at 85-95°C for an additional hour and filtered while hot. The manganese oxide precipitate was washed with water and the washings were combined with the pyridine-water filtrate, then cooled to 5-10°C and filtered to remove the unreacted starting material.
[0055] The product was isolated by acidifying the filtrate with concentrated hydrochloric acid to pH=1-2 and removing the white precipitate by filtration. After washing on the filter with water and drying under reduced pressure 2,5-£/s(2,2,2-trifluoroethoxy)benzoic acid was obtained as white powder in 37.2 g (0.116 mol, 75.2%) yield having a melting point of 1210C to 125°C.
[0056] Example 4
[0057] Preparation of 2,5-ΛΛS(2,2,2-trifluorethoxy)-ΛA(pyrid-2-yl-methyl)benzamide (IV) [0058] 2,5-6/s(2,2,2-trifluoroethoxy)benzoic acid (III) (100 g, 0.314 mol), triethylamine (50.2 ml_) and ethyl acetate (630 ml_) were mixed in a 4-liter 3 neck round bottom flask, fitted with a thermometer, a dropping funnel and a calcium chloride drying tube. The reaction mixture was stirred and cooled to 5 to 100C. A solution of ethyl chloroformate (33.0 ml_, 0.345 mol) in ethyl acetate (315 ml_) was added dropwise to the reaction mixture. Thereafter the reaction mixture was stirred at 5 to 10°C for 30 minutes. A solution of 2-(aminomethyl)pyridine (36.0 ml_, 0.350 mol) in ethyl acetate (315 ml_) was added dropwise to the mixture. The reaction mixture was stirred at 15-25°C for 1 hour. Water (600 ml_) was added, and the aqueous layer was separated and extracted with ethyl acetate (300 ml_). The organic layer was concentrated in vacuo io two thirds of the original volume and hexanes (750 ml_) were added. The resulting suspension was stirred at 5-100C for 1 hour.
[0059] The precipitate was separated by filtration and washed with hexanes (250 ml_). The yield was 116.4g (91.7%) of 2,5-6/s(2,2,2-trifluorethoxy)-Λ/-(pyrid- 2-yl-methyl)benzamide (IV) having a melting point 1010C -1060C.
[0060] Example 5
[0061 ] Preparation of 2,5-£/s(2,2,2-trifluoroethoxy)-Λ£(2- piperidylmethyl)benzamide acetate (V)
[0062] 2,5-^/s(2,2,2-trifluoroethoxy)-Λ/-(pyrid-2-yl-methyl)benzamide (1205 g,
2.88 mol), glacial acetic acid (4000 ml_), 5 percent platinum on carbon with 61 % water content (105.5 g) and 10 percent palladium on carbon with 60% water content (28.7 g) were mixed in a 10 liter autoclave.
[0063] The autoclave with the reaction mixture was heated to 700C while rapid stirring over 20-30 minutes, under a hydrogen pressure of 0.39^106 Pa. Pressure was increased to 0.59*106 Pa. 5 minutes later. Hydrogen uptake stopped within 3 hours at 69-72°C, but hydrogenation was continued for additional 2 hours. The reaction mixture was filtered to remove the catalyst.
[0064] Approximately 60% of the solvent was removed by distillation at reduced pressure. Water (35 L) was added to the distillation residue, the mixture was then treated with an aqueous NaOH solution to pH=13-14. The solid white precipitate was filtered, dried at reduced pressure and dissolved in ethyl acetate (12 L). The solution was heated to 73°C for 5 minutes, filtered and to the filtrate was added glacial acetic acid (175 ml) at 31 °C. The precipitates were separated by filtration and then rinsed with ethyl acetate (500 ml). The damp cake was dried at reduced pressure for 14 hours at 200C to give 2,5-6/s(2,2,2-trifluoroethoxy)-Λ/-(2- piperidylmethyl)benzamide acetate as a white solid in 1173 g (86 %) yield having a melting point of 146 to 152°C.

Claims

Claims
1. A process for preparation of compound of formula Vl:
Figure imgf000015_0001
wherein R is a 2-piperidyl or 2-pyridyl radical, and pharmaceutically acceptable salts thereof, which compromises the steps of: a) reaction of the 2,5-dihalotoluene of formula (I)
Figure imgf000015_0002
m wherein Xi and X2 is halogen, with strong base and 2,2,2-trifluoroethanol in the presence of a catalyst in an aprotic solvent to form 2, 5- £/5(2,2,2- trifluoroethoxy) toluene of formula (II).
Figure imgf000015_0003
ill] b) oxidation of 2,5-£/s(2,2,2-trifluoroethoxy) toluene of formula (II) to yield 2,5- £/s (2,2,2-trifluorethoxy) benzoic acid of formula (III);
Figure imgf000016_0001
c) activating the 2,5-£/s (2,2,2-trifluorethoxy) benzoic acid of formula (III) with carbonic acid ester and reacting the mixed anhydride of benzoic acid with amine of the formula RCH2NH2, where R is 2-pyridyl to obtain 2, 5- £/5(2,2, 2- trifluorethoxy)-Λ/-(pyrid-2-yl-methyl)benzamide of formula (IV);
Figure imgf000016_0002
d) converting the 2,5-£/s(2,2,2-trifluorethoxy)-Λ/-(pyrid-2-yl-methyl)benzamide of formula (IV) to a pharmaceutically acceptable salt thereof to obtain 2,5- £/s(2,2,2-trifluoroethoxy)-M(2-piperidylmethyl)benzamide acetate of formula (V).
Figure imgf000016_0003
2. A process according to claim 1 , as strong base is compromises with metallic sodium, catalyst compromises with copper type catalyst as copper sulphate in step a) is carried out in a suitable aprotic solvent.
3. A process according to claim 2, wherein Λ/,Λ/-di methyl formamide is used as a suitable aprotic solvent in step a).
4. A process according to claim 1 , as oxidant is compromises with potassium or sodium permanganate in step b).
5. A process according to claim 1 , carbonic acid ester is compromises with ethyl chloroformate in step c).
6. A process according to claim 1 , an amine is compromises with 2- (aminomethyl) pyperidine in step c) to obtain 2,5-£/s(2,2,2-trifluorethoxy)- N-(pyrid-2-yl-methyl)-benzamide in carbonic acid ester.
7. A process according to claim 1 , where R is 2-pyridine to obtain 2,5- £/5(2,2,2-trifluoroethoxy)-M(2-piperidylmethyl)benzanriide acetate is step d).
8. A process according to claim 1 , where Xi and X2 is Cl, Br, J and Cl of formula I.
9. A process according claim 8, where Xi and X2 is Br of formula I.
10. A process according claim 1 , where 2,5-dibromotoluene of the formula I.
PCT/EP2007/061820 2006-11-06 2007-11-02 Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidylmethyl)-benzamide and salts thereof Ceased WO2008055851A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US12/312,322 US20100056794A1 (en) 2006-11-06 2007-11-02 Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidyl-methyl)-benzamide and salts thereof
JP2009535082A JP2010508331A (en) 2006-11-06 2007-11-02 Method for preparing 2,5-bis- (2,2,2-trifluoroethoxy) -N- (2-piperidylmethyl) -benzamide and salts thereof
EA200900356A EA200900356A1 (en) 2006-11-06 2007-11-02 METHOD OF OBTAINING 2,5-BIS- (2,2,2-TRIFTOROETOXI) -N- (2-PIPERIDYLMETHYL) BENZAMIDE AND ITS SALTS
CA002660364A CA2660364A1 (en) 2006-11-06 2007-11-02 Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidylmethyl)-benzamide and salts thereof
AU2007316692A AU2007316692A1 (en) 2006-11-06 2007-11-02 Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide and salts thereof
MX2009004648A MX2009004648A (en) 2006-11-06 2007-11-02 Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n- (2-piperidylmethyl)-benzamide and salts thereof.
BRPI0714989-1A BRPI0714989A2 (en) 2006-11-06 2007-11-02 Process for the preparation of 2,5-bis- (2,2,2-trifluroethoxy) -N- (2-piperidylmentyl) -benzamide and its salts
EP07822153A EP2079692A1 (en) 2006-11-06 2007-11-02 Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidylmethyl)-benzamide and salts thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06123547.9 2006-11-06
EP06123547A EP1918280A1 (en) 2006-11-06 2006-11-06 Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide and salts thereof

Publications (2)

Publication Number Publication Date
WO2008055851A1 true WO2008055851A1 (en) 2008-05-15
WO2008055851A8 WO2008055851A8 (en) 2009-04-09

Family

ID=37965028

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2007/061818 Ceased WO2008055849A1 (en) 2006-11-06 2007-11-02 Process for the preparation of trifluoroethoxytoluenes
PCT/EP2007/061820 Ceased WO2008055851A1 (en) 2006-11-06 2007-11-02 Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidylmethyl)-benzamide and salts thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/061818 Ceased WO2008055849A1 (en) 2006-11-06 2007-11-02 Process for the preparation of trifluoroethoxytoluenes

Country Status (14)

Country Link
US (2) US20100063292A1 (en)
EP (3) EP1918280A1 (en)
JP (2) JP2010508330A (en)
KR (2) KR20090055638A (en)
CN (2) CN101516845A (en)
AT (1) ATE514670T1 (en)
AU (2) AU2007316690A1 (en)
BR (2) BRPI0714991A2 (en)
CA (2) CA2660358A1 (en)
EA (2) EA200900356A1 (en)
MX (2) MX2009004648A (en)
PL (1) PL2079674T3 (en)
WO (2) WO2008055849A1 (en)
ZA (2) ZA200902184B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102977003A (en) * 2012-11-28 2013-03-20 郑州大明药物科技有限公司 Preparation method of flecainide acetate
CN111018694A (en) * 2019-12-12 2020-04-17 贵州省欣紫鸿药用辅料有限公司 Production method of flecainide
CN115368786B (en) * 2022-08-15 2023-05-09 江阴市华昌不锈钢管有限公司 Preparation process of super austenitic high-temperature-resistant corrosion-resistant stainless steel welded pipe
CN116120146B (en) * 2022-08-18 2024-01-16 浙江省化工研究院有限公司 A kind of production method and system of hexafluorobutadiene
CN117385378B (en) * 2023-10-13 2024-09-24 厦门大学 Electrooxidation preparation method and application of electron-deficient aromatic acetal

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3900481A (en) * 1974-04-01 1975-08-19 Riker Laboratories Inc Derivatives of pyrrolidine and piperidine
WO1998047853A1 (en) * 1997-04-21 1998-10-29 Finetech Ltd. Process for the preparation of trifluoroethoxyarenecarboxylic acids
WO2001090062A2 (en) * 2000-05-26 2001-11-29 Merck Patent Gmbh Method for the production of trifluoroethoxy-substituted benzoic acids
WO2002004419A2 (en) * 2000-07-12 2002-01-17 Geneva Pharmaceuticals, Inc. α,α-DIBROMO-α-CHLORO-ACETOPHENONES AS SYNTHONS
EP1283201A1 (en) * 2001-08-10 2003-02-12 A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A. Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidyl-methyl)-benzamide (flecanide)
US20050059825A1 (en) * 2003-09-17 2005-03-17 Zhi-Xian Wang Novel process for the preparation of flecainide, its pharmaceutically acceptable salts and important intermediates thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617396A (en) * 1979-03-19 1986-10-14 Riker Laboratories, Inc. Process for the preparation of derivatives of piperidine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3900481A (en) * 1974-04-01 1975-08-19 Riker Laboratories Inc Derivatives of pyrrolidine and piperidine
WO1998047853A1 (en) * 1997-04-21 1998-10-29 Finetech Ltd. Process for the preparation of trifluoroethoxyarenecarboxylic acids
WO2001090062A2 (en) * 2000-05-26 2001-11-29 Merck Patent Gmbh Method for the production of trifluoroethoxy-substituted benzoic acids
WO2002004419A2 (en) * 2000-07-12 2002-01-17 Geneva Pharmaceuticals, Inc. α,α-DIBROMO-α-CHLORO-ACETOPHENONES AS SYNTHONS
EP1283201A1 (en) * 2001-08-10 2003-02-12 A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A. Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidyl-methyl)-benzamide (flecanide)
US20050059825A1 (en) * 2003-09-17 2005-03-17 Zhi-Xian Wang Novel process for the preparation of flecainide, its pharmaceutically acceptable salts and important intermediates thereof

Also Published As

Publication number Publication date
ZA200902184B (en) 2010-03-31
AU2007316690A1 (en) 2008-05-15
EP2079692A1 (en) 2009-07-22
CN101516845A (en) 2009-08-26
ATE514670T1 (en) 2011-07-15
ZA200902183B (en) 2010-07-28
EP2079674A1 (en) 2009-07-22
MX2009004647A (en) 2009-05-20
AU2007316692A1 (en) 2008-05-15
KR20090055638A (en) 2009-06-02
WO2008055849A1 (en) 2008-05-15
PL2079674T3 (en) 2011-11-30
KR20090064456A (en) 2009-06-18
MX2009004648A (en) 2009-05-21
JP2010508330A (en) 2010-03-18
EA200900356A1 (en) 2009-10-30
CA2660358A1 (en) 2008-05-15
EP1918280A1 (en) 2008-05-07
JP2010508331A (en) 2010-03-18
EA200900357A1 (en) 2009-10-30
US20100056794A1 (en) 2010-03-04
BRPI0714991A2 (en) 2013-07-30
EP2079674B1 (en) 2011-06-29
BRPI0714989A2 (en) 2013-07-30
CA2660364A1 (en) 2008-05-15
US20100063292A1 (en) 2010-03-11
CN101516817A (en) 2009-08-26
WO2008055851A8 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
CN112707836B (en) Preparation method of m-diamide compound
BG107635A (en) METHOD FOR PREPARING N-Aryl-ANTANILIC ACIDS AND THEIR DERIVATIVES
CA2988594C (en) Methods of making protein deacetylase inhibitors
JPH01104045A (en) Manufacture of 2,5-bis(2,2,2-trifluoroethoxy)- n-(2-piperidylmethyl)benzamide
WO2008055851A1 (en) Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidylmethyl)-benzamide and salts thereof
EP2358678B1 (en) Process for manufacturing 5-chloromethyl-2,3-pyridine dicarboxylic acid anhydrides
CN104837817B (en) Synthetic route for preparation of 3-amino-piperidine compounds
EP2982673B1 (en) Process for manufacturing 5-chloromethyl-2,3-dicarboxylic anhydride
US7196197B2 (en) Process for the preparation of Flecainide, its pharmaceutically acceptable salts and important intermediates thereof
CN114560862A (en) Synthesis method of pyrrolo [1,2-A ] quinoxaline-4 (5H) -ketone and derivative thereof
US6573384B1 (en) Process for production of indole derivatives and intermediates therefor
CN115197086A (en) Preparation method of difluoro methoxy-containing m-diamide compound
CN115043845B (en) A kind of synthesis method of sildenafil
KR20140127651A (en) Novel Process For Preparation Of 4-(4-Aminophenyl)-3-Morpholinone
US20070149606A1 (en) Process for producing phenylacetic acid derivative
WO2010061621A1 (en) Method for manufacturing trans-{4-[(alkyl amino) methyl] cyclohexyl} acetic ester
CN121779296A (en) A method for preparing an intermediate for the preparation of vonoprazan fumarate
CN119954778A (en) A method for synthesizing lenacapvir sodium and its series of intermediate compounds
CN116621813A (en) A kind of preparation and purification method of vornosuran fumarate
CN120435453A (en) A novel method for preparing MDM2-p53 antagonists
KR101059275B1 (en) Process for preparing improved 4- [2- (di-ene-propylamino) ethyl] -1,3-dihydro-2H-indol-2-one
KR20120069710A (en) Process for production of 4-(5-methylpyridin-2-ylamino)piperidine-1-carboxylic acid derivatives
JPH0616624A (en) 3-amino-4,4-dialkylpyrrolidine derivative
KR20000037954A (en) Method for preparing [2- (2,6-dichloroanilino) phenyl] acetoxyacetic acid

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780035853.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07822153

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007822153

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2660364

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 575124

Country of ref document: NZ

Ref document number: 2007316692

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 11141

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 887/KOLNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007316692

Country of ref document: AU

Date of ref document: 20071102

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200900356

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1020097007909

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/004648

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009535082

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12312322

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: PI0714989

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090309